Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Jeffrey Trigilio net worth and biography

Jeffrey Trigilio Biography and Net Worth

CFO of Cullinan Oncology

Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Cullinan Oncology, Jeff most recently served as CFO at Amylyx Pharmaceuticals where he established the company’s Finance and Accounting operations and oversaw the successful completion of a Series B financing. Jeff joined Amylyx after serving as a Vice President at BlueRock Therapeutics, an engineered cell and gene therapy company, where he played a leading role in building out the finance function and supporting its sale to Bayer AG in a transaction that valued BlueRock up to $1 billion. Previously, Jeff held corporate finance and strategy roles at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, and in Healthcare Investment Banking and Equity Capital Markets at RBC Capital Markets and Credit Suisse.

What is Jeffrey Trigilio's net worth?: The estimated net worth of Jeffrey Trigilio is at least $1.30 million as of December 21st, 2023. Mr. Trigilio owns 83,919 shares of Cullinan Oncology stock worth more than $1,300,745 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Trigilio may own. Learn More about Jeffrey Trigilio's net worth.
How do I contact Jeffrey Trigilio?: The corporate mailing address for Mr. Trigilio and other Cullinan Oncology executives is , , . Cullinan Oncology can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Jeffrey Trigilio's contact information.
Has Jeffrey Trigilio been buying or selling shares of Cullinan Oncology?: Jeffrey Trigilio has not been actively trading shares of Cullinan Oncology within the last three months. Most recently, Jeffrey Trigilio sold 1,920 shares of the business's stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $8.50, for a transaction totalling $16,320.00. Following the completion of the sale, the chief financial officer now directly owns 83,919 shares of the company's stock, valued at $713,311.50. Learn More on Jeffrey Trigilio's trading history.
Who are Cullinan Oncology's active insiders?: Cullinan Oncology's insider roster includes Nadim Ahmed (Pres), Ansbert Gadicke (Director), Jennifer Michaelson (Insider), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Oncology's active insiders.
Are insiders buying or selling shares of Cullinan Oncology?: During the last twelve months, insiders at the sold shares 22 times. They sold a total of 127,055 shares worth more than $1,735,238.12. The most recent insider tranaction occured on February, 1st when insider Corrine Savill sold 40,000 shares worth more than $647,200.00. Insiders at Cullinan Oncology own 8.8% of the company. Learn More about insider trades at Cullinan Oncology.
Information on this page was last updated on 2/1/2024.

Jeffrey Trigilio Insider Trading History at Cullinan Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/21/2023	Sell	1,920	$8.50	$16,320.00	83,919
12/18/2023	Sell	398	$8.22	$3,271.56	85,839
12/12/2023	Sell	1,926	$7.81	$15,042.06	86,237
6/20/2023	Sell	399	$12.94	$5,163.06	85,823
6/12/2023	Sell	319	$13.11	$4,182.09	86,222
5/18/2023	Sell	399	$8.76	$3,495.24	86,541
5/12/2023	Sell	347	$8.78	$3,046.66	86,940
4/18/2023	Sell	398	$10.71	$4,262.58	87,287
4/12/2023	Sell	318	$10.22	$3,249.96	87,685
3/20/2023	Sell	399	$11.32	$4,516.68	88,003
10/15/2021	Sell	8,000	$25.00	$200,000.00

Jeffrey Trigilio Buying and Selling Activity at Cullinan Oncology

Cullinan Oncology Company Overview

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $15.50

$15.20

$18.26

50 Day Range

MA: $17.29

$15.32

$19.02

2 Week Range

Now: $15.50

$7.64

$20.62

Volume

731,790 shs

Average Volume

462,768 shs

Market Capitalization

$667.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Secure Your Spot Now